Aprea Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.75 Insider Own2.50% Shs Outstand21.54M Perf Week-44.62%
Market Cap13.13M Forward P/E- EPS next Y-1.43 Insider Trans5.06% Shs Float19.77M Perf Month-55.77%
Income-37.10M PEG- EPS next Q-0.38 Inst Own26.70% Short Float4.75% Perf Quarter-62.77%
Sales- P/S- EPS this Y31.10% Inst Trans-2.97% Short Ratio2.31 Perf Half Y-84.49%
Book/sh2.30 P/B0.29 EPS next Y11.70% ROA-54.70% Target Price3.00 Perf Year-84.46%
Cash/sh2.67 P/C0.25 EPS next 5Y- ROE-63.70% 52W Range0.62 - 7.80 Perf YTD-77.04%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-91.55% Beta-
Dividend %- Quick Ratio7.70 Sales past 5Y- Gross Margin- 52W Low6.29% ATR0.14
Employees16 Current Ratio7.70 Sales Q/Q- Oper. Margin- RSI (14)22.61 Volatility22.62% 13.42%
OptionableYes Debt/Eq0.00 EPS Q/Q50.40% Profit Margin- Rel Volume2.56 Prev Close0.65
ShortableYes LT Debt/Eq0.00 EarningsMar 15 AMC Payout- Avg Volume406.28K Price0.66
Recom3.20 SMA20-47.21% SMA50-57.71% SMA200-79.20% Volume1,038,713 Change1.92%
Dec-28-20Downgrade Robert W. Baird Outperform → Neutral
Dec-16-20Initiated Berenberg Buy $37
Sep-29-20Resumed JP Morgan Neutral $25
Jun-22-20Initiated H.C. Wainwright Neutral $30
Apr-21-20Initiated Robert W. Baird Outperform $45
Oct-28-19Initiated RBC Capital Mkts Outperform $33
Oct-28-19Initiated Morgan Stanley Equal-Weight $23
Oct-28-19Initiated JP Morgan Neutral $23
May-19-22 06:30AM  
May-16-22 09:21AM  
Mar-15-22 04:15PM  
Mar-02-22 04:41AM  
Jan-14-22 10:00AM  
Jan-06-22 08:00AM  
Dec-14-21 08:00AM  
Dec-13-21 08:00AM  
Dec-10-21 10:30AM  
Dec-09-21 12:30PM  
Nov-08-21 04:15PM  
Nov-04-21 04:15PM  
Sep-21-21 08:39AM  
Sep-20-21 04:15PM  
Sep-14-21 08:00AM  
Sep-03-21 07:21AM  
Aug-12-21 04:15PM  
Aug-05-21 05:00PM  
Jul-21-21 08:00AM  
Jun-18-21 08:34AM  
Jun-17-21 09:19AM  
Jun-16-21 09:24AM  
Jun-13-21 12:45PM  
Jun-04-21 01:47AM  
May-21-21 06:00AM  
May-18-21 06:00AM  
May-06-21 04:15PM  
Apr-16-21 09:15AM  
Apr-08-21 11:15AM  
Mar-16-21 04:15PM  
Feb-16-21 08:04AM  
Jan-22-21 12:00PM  
Jan-08-21 08:00AM  
Dec-30-20 11:40AM  
Dec-29-20 07:24PM  
Dec-28-20 04:57PM  
Dec-10-20 10:33PM  
Nov-30-20 08:00AM  
Nov-23-20 10:00AM  
Nov-19-20 08:00AM  
Nov-05-20 04:15PM  
Oct-30-20 04:00AM  
Oct-14-20 08:00AM  
Oct-07-20 08:00AM  
Sep-29-20 08:00AM  
Sep-18-20 08:00AM  
Sep-03-20 08:00AM  
Aug-11-20 04:15PM  
Jul-16-20 07:00AM  
Jul-01-20 10:32AM  
Jun-29-20 07:00AM  
Jun-12-20 04:15PM  
Jun-11-20 10:44PM  
Jun-10-20 09:39AM  
Jun-03-20 08:00AM  
May-27-20 09:21AM  
May-18-20 08:00AM  
May-15-20 07:30AM  
May-11-20 10:57AM  
Apr-27-20 07:00AM  
Apr-06-20 08:00AM  
Apr-02-20 06:11AM  
Mar-26-20 08:00AM  
Feb-13-20 08:00AM  
Jan-30-20 07:30AM  
Jan-09-20 08:00AM  
Jan-03-20 05:56AM  
Dec-17-19 10:08AM  
Dec-12-19 08:30AM  
Dec-09-19 11:00AM  
Dec-07-19 08:35AM  
Nov-29-19 09:24AM  
Nov-14-19 04:15PM  
Nov-11-19 04:40PM  
Nov-06-19 09:15AM  
Oct-11-19 05:01PM  
Oct-08-19 03:59PM  
Oct-07-19 04:15PM  
Oct-03-19 11:09AM  
Oct-02-19 11:03PM  
Sep-30-19 10:21AM  
Sep-23-19 08:55AM  
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Seizinger Bernd R.DirectorMay 18Buy0.7150,00035,500318,580May 19 04:31 PM
SCHADE CHRISTIAN SChairman & CEOMay 18Buy0.6437,50024,124292,616May 19 04:30 PM
Attar Eyal C.SVP, Chief Medical OfficerFeb 28Sale1.7336,00062,28047,000Mar 01 05:01 PM
Korbel Gregory AlanSVP, Chief Business OfficerDec 01Option Exercise0.9227,50025,30044,667Dec 03 05:01 PM
Korbel Gregory AlanSVP, Chief Business OfficerDec 01Sale3.9627,500108,90017,167Dec 03 05:01 PM
Korbel Gregory AlanSVP, Chief Business OfficerNov 01Option Exercise0.9227,50025,30044,667Nov 03 05:34 PM
Korbel Gregory AlanSVP, Chief Business OfficerNov 01Sale5.0027,500137,50017,167Nov 03 05:34 PM
Abrahmsen Lars B.SVP, Chief Scientific OfficerOct 01Option Exercise0.9250,00046,00069,000Oct 05 05:01 PM
Korbel Gregory AlanSVP, Chief Business OfficerOct 01Option Exercise0.9227,50025,30044,667Oct 05 05:01 PM
Korbel Gregory AlanSVP, Chief Business OfficerOct 01Sale4.8927,500134,47517,167Oct 05 05:01 PM
Abrahmsen Lars B.SVP, Chief Scientific OfficerOct 01Sale4.8950,000244,50019,000Oct 05 05:01 PM
Abrahmsen Lars B.SVP, Chief Scientific OfficerSep 20Option Exercise0.9225,00023,00044,000Sep 22 05:00 PM
Korbel Gregory AlanSVP, Chief Business OfficerSep 20Option Exercise0.9227,50025,30044,667Sep 22 05:01 PM
Abrahmsen Lars B.SVP, Chief Scientific OfficerSep 20Sale4.9725,000124,25019,000Sep 22 05:00 PM
Korbel Gregory AlanSVP, Chief Business OfficerSep 20Sale4.9732,960163,86617,167Sep 22 05:01 PM
Attar Eyal C.SVP, Chief Medical OfficerSep 16Sale4.6815,96874,73083,000Sep 20 05:29 PM